Merck to buy cancer drug developer Peloton for $1.05 bln in cash

Credit: REUTERS/Brendan McDermid

Adds details on Peloton's drug candidate, IPO filing, background

May 21 (Reuters) - Merck & Co Inc MRK.N said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company's renal cancer drug candidate.

The company's lead drug candidate, PT2977, will be studied in a late-stage study for treating renal cell carcinoma.

Peloton shareholders will be eligible to receive a further $1.15 billion on achieving certain milestones.

The company had been looking to go public and gave a pricing range of $15 to $17 per share for its initial public offering last week.

Credit Suisse acted as financial adviser for Merck and Covington & Burling LLP as its legal adviser. Centerview Partners was financial adviser to Peloton and Wilson Sonsini Goodrich & Rosati was its legal adviser.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

((; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.